RN
Therapeutic Areas
UroGen Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JELMYTO® (UGN-101) | Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) | Approved |
| UGN-102 | Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) | Phase 3 |
| UGN-301 (zalifrelimab) | Locally advanced or metastatic solid tumors | Phase 1/2 |
| UGN-302 | Undisclosed oncology target | Preclinical |
Leadership Team at UroGen Pharma
LB
Liz Barrett
President and Chief Executive Officer
MT
Mohit Trikha
Chief Technical Officer
PP
Peter P. Pfreundschuh
Chief Financial Officer
MP
Mark P. Schoenberg
Chief Medical Officer
CL
Cynthia L. Flowers
Chief Commercial Officer
AB
Arie Belldegrun
Director
SH
Stuart Holden
Director
SB
Sharon Barbari
Director
JR
James Robinson
Director
MG
Michael G. Jesselson
Director